Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
Related Content